Melatonin and 5‐fluorouracil co‐suppress colon cancer stem cells by regulating cellular prion protein‐Oct4 axis. Issue 4 (24th August 2018)

• Record Type: Journal Article
• Authors: Lee, Jun Hee; Yun, Chul Won; Han, Yong‐Seok; Kim, SangMin; Jeong, Dongjun; Kwon, Hyog Young; Kim, Hyeongjoo; Baek, Moo‐Jun; Lee, Sang Hun
• Is Part Of: Journal of pineal research. Volume 65:Issue 4(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-08-24
• Subjects: cancer stem cell -- cellular prion protein -- melatonin -- Oct4; Pineal gland -- Periodicals; Pineal Gland -- Periodicals; Épiphyse (Glande); Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 612.492
• DOI: 10.1111/jpi.12519
• Languages: English
• ISSNs: 0742-3098

Abstract

Abstract: Melatonin suppresses tumor development. However, the exact relationship between melatonin and cancer stem cells (CSCs) is poorly understood. This study found that melatonin inhibits colon CSCs by regulating the PrP C ‐Oct4 axis. In specimens from patients with colorectal cancer, the expressions of cellular prion protein (PrP C ) and Oct4 were significantly correlated with metastasis and tumor stages. Co‐treatment with 5‐fluorouracil (5‐FU) and melatonin inhibited the stem cell markers Oct4, Nanog, Sox2, and ALDH1A1 by downregulating PrP C . In this way, tumor growth, proliferation, and tumor‐mediated angiogenesis were suppressed. In colorectal CSCs, PRNP overexpression protects Oct4 against inhibition by 5‐FU and melatonin. In contrast, Nanog, Sox2, and ALDH1A1 have no such protection. These results indicate that PrP C directly regulates Oct4, whereas it indirectly regulates Nanog, Sox2, and ALDH1A1. Taken together, our findings suggest that co‐treatment with anticancer drug and melatonin is a potential therapy for colorectal cancer. Furthermore, PrP C maintains cancer stemness during tumor progression. Therefore, targeting the PrP C ‐Oct4 axis may prove instrumental in colorectal cancer therapy.